Comparative Oncology: Dogs, Cats, And Man

1972 ◽  
Vol 15 (4) ◽  
pp. 507-519 ◽  
Author(s):  
C. Richard Dorn
Keyword(s):  
2018 ◽  
Vol 17 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Michael Willmann ◽  
Emir Hadzijusufovic ◽  
Olivier Hermine ◽  
Mauro Dacasto ◽  
Laura Marconato ◽  
...  

2014 ◽  
pp. 1-4
Author(s):  
Melissa C. Paoloni ◽  
Chand Khanna
Keyword(s):  

1959 ◽  
pp. 85-98 ◽  
Author(s):  
JOSEPH G. FORTNER ◽  
ARTHUR C. ALLEN
Keyword(s):  

Genes ◽  
2019 ◽  
Vol 10 (7) ◽  
pp. 501 ◽  
Author(s):  
Prouteau ◽  
André

Despite recent genetic advances and numerous ongoing therapeutic trials, malignant melanoma remains fatal, and prognostic factors as well as more efficient treatments are needed. The development of such research strongly depends on the availability of appropriate models recapitulating all the features of human melanoma. The concept of comparative oncology, with the use of spontaneous canine models has recently acquired a unique value as a translational model. Canine malignant melanomas are naturally occurring cancers presenting striking homologies with human melanomas. As for many other cancers, dogs present surprising breed predispositions and higher frequency of certain subtypes per breed. Oral melanomas, which are much more frequent and highly severe in dogs and cutaneous melanomas with severe digital forms or uveal subtypes are subtypes presenting relevant homologies with their human counterparts, thus constituting close models for these human melanoma subtypes. This review addresses how canine and human melanoma subtypes compare based on their epidemiological, clinical, histological, and genetic characteristics, and how comparative oncology approaches can provide insights into rare and poorly characterized melanoma subtypes in humans that are frequent and breed-specific in dogs. We propose canine malignant melanomas as models for rare non-UV-induced human melanomas, especially mucosal melanomas. Naturally affected dogs offer the opportunity to decipher the genetics at both germline and somatic levels and to explore therapeutic options, with the dog entering preclinical trials as human patients, benefiting both dogs and humans.


JAMA Oncology ◽  
2018 ◽  
Vol 4 (6) ◽  
pp. 874 ◽  
Author(s):  
Bo Huang ◽  
Lu Tian ◽  
Enayet Talukder ◽  
Mace Rothenberg ◽  
Dae Hyun Kim ◽  
...  

2015 ◽  
Author(s):  
Joy M. Fulbright ◽  
Kathleen Neville ◽  
Melinda Broward ◽  
Tyce A. Bruns ◽  
Anuradha Roy ◽  
...  

2020 ◽  
Vol 51 (4) ◽  
pp. 425-439
Author(s):  
Alejandro Clavijo-Maldonado ◽  
Enio Ferreira ◽  
Carlos Vargas-Hernández ◽  
Fredy A. Rivera-Páez

Canine mammary cancer (CMC) is one of the most common neoplasms in intact females in comparison to other species. Several risk factors have been identified, including breed, genetic predisposition, age, reproductive history, hormonal influence, diet, and body condition, in addition to previous lesions to the mammary gland, such as mammary atypical hyperplasia. An understanding of the genetic markers for the disease and a clinical approach are important for establishing a specific therapy that can allow adequate patient survivorship. Overexpression of the HER-2 gene in canines and humans is associated with a poor clinical prognosis, mainly short survivorship, although the clinical relationship is not clear. The incidence of HER-2 in female dogs can range from 29.7% to 38%. However, overexpression of HER-2 is not necessarily associated with malignancy processes of the mammary tissue, although it participates in cellular proliferation. Finally, canines remain one of the most important models for comparative oncology with humans due to the great similarity in the spontaneous presentation and development of cancer, and in the high homology in the amino acid sequence.


Sign in / Sign up

Export Citation Format

Share Document